Patents Assigned to Teva Pharmaceutical Industries Ltd.
-
Patent number: 9585878Abstract: This application provides for a method of increasing brain-derived neurotrophic factor (BDNF) serum level in a human subject comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to increase BDNF serum level in the human subject. The method can further comprise periodically administering to the subject an amount of a second BDNF-increasing agent. This application also provides for a method for treating a human subject suffering from a BDNF-related disease comprising periodically administering laquinimod or a pharmaceutically acceptable salt thereof in an amount effective to treat the human subject. This application additionally provides for use of laquinimod in the manufacture of a medicament for increasing BDNF serum level in a human subject. This application further provides for a pharmaceutical composition comprising an amount of laquinimod effective for use in increasing BDNF serum level in a human subject.Type: GrantFiled: August 9, 2010Date of Patent: March 7, 2017Assignee: TEVA PHARMACEUTICAL INDUSTRIES, LTD.Inventor: Liat Hayardeny
-
Publication number: 20170028013Abstract: A stable pharmaceutical composition comprising a therapeutically effective amount of laquinimod, a therapeutically effective amount of glatiramer acetate related drug substance, and an amount of an amino acid. A process for making a stable pharmaceutical in liquid form, a sealed package comprising a stable pharmaceutical composition as described herein, and a use of a stable pharmaceutical composition as described herein. A method for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome, alleviating a symptom of multiple sclerosis in a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome, and/or providing neuroprotection to a subject in need thereof, comprising administering to the subject a composition as described herein.Type: ApplicationFiled: July 28, 2016Publication date: February 2, 2017Applicant: Teva Pharmaceutical Industries, Ltd.Inventors: Galina Linden, Rakefet Cohen, Danit Licht
-
Publication number: 20170027927Abstract: The subject invention provides a method of treating a subject afflicted with glaucoma, suffering from retinal ganglion cell (RGC) loss or damage, or elevated intraocular pressure (IOP), or of reducing RGC loss or damage, or reducing IOP in a subject, comprising administering to the subject an amount of laquinimod effective to treat the subject, to reduce RGC loss or damage, or to reduce IOP in the subject. Provide also is a pharmaceutical composition, a package and a therapeutic package for treating a subject afflicted with glaucoma.Type: ApplicationFiled: October 11, 2016Publication date: February 2, 2017Applicant: Teva Pharmaceutical Industries, Ltd.Inventors: Ron Neumann, Revital Etzyoni
-
Publication number: 20170020857Abstract: This application provides for a method of treating a subject suffering from Crohn's disease, the method comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This application provides for use of laquinimod in the manufacture of a medicament for treating a subject suffering from Crohn's disease. This application also provides for a pharmaceutical composition comprising laquinimod for use in treating a subject suffering from Crohn's disease.Type: ApplicationFiled: October 6, 2016Publication date: January 26, 2017Applicant: Teva Pharmaceutical Industries, Ltd.Inventors: Nora Tarcic, Asi Haviv, Eran Blaugrund, Joel Kaye
-
Publication number: 20170007596Abstract: This invention provides a method of treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the subject laquinimod as an add-on therapy to or in combination with flupirtine. This invention also provides a package and a pharmaceutical composition comprising laquinimod and flupirtine for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides laquinimod for use as an add-on therapy or in combination with flupirtine in treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention further provides use of laquinimod and flupirtine in the preparation of a combination for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome.Type: ApplicationFiled: June 7, 2016Publication date: January 12, 2017Applicant: Teva Pharmaceutical Industries, Ltd.Inventors: David Silver, Einat Amit Romach
-
Patent number: 9526858Abstract: An inhaler for inhalation into the airway of a user, the inhaler having a housing at least partially defining a flow passageway extending through the inhaler from an air inlet to an outlet, the inhaler including a valve for selectively restricting the flow passageway.Type: GrantFiled: November 30, 2011Date of Patent: December 27, 2016Assignee: Teva Pharmaceuticals Industries Ltd.Inventor: Krijn Franciscus Marie Zuyderhoudt
-
Publication number: 20160361352Abstract: This invention provides a method of treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the patient laquinimod as an add-on therapy to or in combination with glatiramer acetate. This invention also provides a package and a pharmaceutical composition comprising laquinimod and glatiramer acetate for treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides laquinimod for use as an add-on therapy or in combination with glatiramer acetate in treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention further provides use of laquinimod and glatiramer acetate in the preparation of a combination for treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome.Type: ApplicationFiled: May 6, 2016Publication date: December 15, 2016Applicant: Teva Pharmaceutical Industries, Ltd.Inventors: Yossi Gilgun, Nora Tarcic
-
Patent number: 9499868Abstract: This invention provides a method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of 1) identifying whether the human subject is a predicted responder to glatiramer acetate by determining the genotype of the subject at one or more single nucleotide polymorphisms (SNPs) selected from the group consisting of the SNPs in Group 1; and 2) administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the subject only if the subject is identified as a predicted responder to glatiramer acetate.Type: GrantFiled: August 25, 2014Date of Patent: November 22, 2016Assignee: TEVA PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Amir Tchelet, Fabio Macciardi, Joseph Levy
-
Publication number: 20160331742Abstract: This invention provides a method of treating a subject suffering from Crohn's disease, comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject, which amount of laquinimod is less than 0.5 mg/day, wherein the subject is naïve to laquinimod and the administration continues for at least 12 weeks, or wherein the subject is being treated with another Crohn's disease therapy at baseline. Furthermore, this invention provides a corresponding therapeutic package, use of laquinimod or pharmaceutically acceptable salt thereof in the manufacture of a medicament, and pharmaceutical composition.Type: ApplicationFiled: January 15, 2015Publication date: November 17, 2016Applicant: Teva Pharmaceutical Industries, Ltd.Inventors: Kurt A Brown, Ella Sorani
-
Publication number: 20160317525Abstract: This invention provides a method of treating a subject afflicted with multiple sclerosis (MS) or presenting a clinically isolated syndrome (CIS) comprising administering to the subject laquinimod as an add-on therapy to or in combination with a greater than minimal effective dose of teriflunomide. This invention also provides a package and a pharmaceutical composition comprising laquinimod and a greater than minimal effective dose of teriflunomide for treating a subject afflicted with MS or presenting a CIS. This invention also provides laquinimod for use as an add-on therapy or in combination with a greater than minimal effective dose of teriflunomide in treating a subject afflicted with MS or presenting a CIS. This invention further provides use of laquinimod and a greater than minimal effective dose of teriflunomide in the preparation of a combination for treating a subject afflicted with MS or presenting a CIS.Type: ApplicationFiled: December 23, 2014Publication date: November 3, 2016Applicant: Teva Pharmaceutical Industries, Ltd.Inventor: Volker Knappertz
-
Publication number: 20160317471Abstract: Disclosed are methods for the treatment of Restless Legs Syndrome comprising administering an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: April 11, 2016Publication date: November 3, 2016Applicant: Teva Pharmaceutical Industries, Ltd.Inventors: Eran Blaugrund, Ruth Levy
-
Publication number: 20160310481Abstract: This invention provides a method of treating a human subject suffering from a CB1 receptor related disorder comprising periodically administering to the subject an effective amount of laquinimod or pharmaceutically acceptable salt thereof in an amount effective to treat the subject.Type: ApplicationFiled: March 23, 2016Publication date: October 27, 2016Applicant: Teva Pharmaceutical Industries, Ltd.Inventors: Gianvito Martino, Diego Centonze
-
Publication number: 20160312284Abstract: The present invention provides a method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of: (i) determining a genotype of the subject at a location corresponding to the location of one or more single nucleotide polymorphisms (SNPs) selected from the group consisting of: rs1894408, kgp7747883, kgp6599438, rs10162089, rs16886004, kgp8110667, kgp8817856, kgp24415534, kgp6214351 and rs759458, (ii) identifying the subject as a predicted responder to glatiramer acetate if the genotype of the subject contains one or more A alleles at the location of kgp8110667, rs10162089, rs759458 and kgp6214351, or one or more G alleles at the location of kgp24415534, kgp6599438, kgp7747883, kgp8817856, rs16886004 and rs1894408; and (iii) administering the pharmaceutical composition comprising glatiramer acetate and a pharmaType: ApplicationFiled: April 19, 2016Publication date: October 27, 2016Applicant: Teva Pharmaceutical Industries, Ltd.Inventors: Iris Grossman, Michael Hayden, Colin James Douglas Ross, Daphna Laifenfeld, Matthew Davis
-
Publication number: 20160296473Abstract: The present invention provides improved formulations of 6-mercaptopurine that exhibit better bioavailability and faster dissolution than previous formulations.Type: ApplicationFiled: June 17, 2016Publication date: October 13, 2016Applicant: TEVA PHARMACEUTICAL INDUSTRIES LTD.Inventors: E. Itzhak Lerner, Moshe Flashner-Barak, Erwin v Achthoven, Hans Keegstra, Ruud Smit
-
Publication number: 20160296511Abstract: This invention provides methods for inhibiting or reducing thalamic damage in a subject comprising administering to the subject an amount of laquinimod, wherein the subject is a human patient afflicted with a form of multiple sclerosis or presenting a clinically isolated syndrome who has been determined to have thalamic damage at baseline, a subject afflicted with a disease or disorder other than a form of multiple sclerosis or a clinically isolated syndrome, or a subject not afflicted with a form of multiple sclerosis or a presenting clinically isolated syndrome, and laquinimod and laquinimod pharmaceutical compositions for use thereof. This invention also provides methods for inhibiting or reducing tremor or spasticity in a subject afflicted by tremor or spasticity, comprising administering to the subject an amount of laquinimod, and laquinimod and laquinimod pharmaceutical compositions for use thereof.Type: ApplicationFiled: June 17, 2016Publication date: October 13, 2016Applicant: Teva Pharmaceutical Industries, Ltd.Inventors: Massimo Filippi, Giancarlo Comi, Maria Assunta Rocca
-
Publication number: 20160296513Abstract: This invention provides a method of treating a subject afflicted with multiple sclerosis (MS) or presenting clinically isolated syndrome (CIS) which comprises a) administering to the subject an amount of an anti-CD52 antibody, followed by b) periodically administering to the subject an amount of laquinimod. This invention also provides packages comprising pharmaceutical compositions of laquinimod or an anti-CD52 antibody for treating such a subject wherein laquinimod is to be administered as a maintenance therapy in such a subject who has received an anti-CD52 antibody induction therapy.Type: ApplicationFiled: June 22, 2016Publication date: October 13, 2016Applicant: Teva Pharmaceutical Industries Ltd.Inventor: Volker Knappertz
-
Publication number: 20160296512Abstract: This application provides for a method of treating a subject suffering from Crohn's disease, the method comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This application provides for use of laquinimod in the manufacture of a medicament for treating a subject suffering from Crohn's disease. This application also provides for a pharmaceutical composition comprising laquinimod for use in treating a subject suffering from Crohn's disease.Type: ApplicationFiled: June 20, 2016Publication date: October 13, 2016Applicant: Teva Pharmaceutical Industries, Ltd.Inventors: Nora Tarcic, Asi Haviv, Eran Blaugrund, Joel Kaye
-
Publication number: 20160271094Abstract: The subject invention provides a method for treating a subject afflicted with a form of multiple sclerosis (MS) or presenting a clinically isolated syndrome (CIS) comprising periodically administering to the subject an amount of laquinimod and an amount of a compound of formula (I): as described herein. The subject invention also provides packages and pharmaceutical compositions comprising laquinimod and a compound of formula (I) as described herein. The subject invention further provides uses of said compounds, pharmaceutical compositions and packages in treating a subject afflicted with a form of MS or presenting a CIS.Type: ApplicationFiled: May 31, 2016Publication date: September 22, 2016Applicant: Teva Pharmaceutical Industries, Ltd.Inventors: Volker Knappertz, Joel Kaye
-
Publication number: 20160243103Abstract: This application provides for a method of increasing brain-derived neurotrophic factor (BDNF) serum level in a human subject comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to increase BDNF serum level in the human subject. The method can further comprise periodically administering to the subject an amount of a second BDNF-increasing agent. This application also provides for a method for treating a human subject suffering from a BDNF-related disease comprising periodically administering laquinimod or a pharmaceutically acceptable salt thereof in an amount effective to treat the human subject. This application additionally provides for use of laquinimod in the manufacture of a medicament for increasing BDNF serum, level in a human subject. This application further provides for a pharmaceutical composition comprising an amount of laquinimod effective for use in increasing BDNF serum level in a human subject.Type: ApplicationFiled: February 22, 2016Publication date: August 25, 2016Applicant: Teva Pharmaceutical Industries, Ltd.Inventor: Liat Hayardeny
-
Publication number: 20160235735Abstract: This invention provides a method of treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the subject fampridine as an add-on therapy to or in combination with laquinimod. This invention also provides a package comprising laquinimod and fampridine for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides fampridine for use as an add-on therapy or in combination with laquinimod in treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides a pharmaceutical composition comprising laquinimod and fampridine for use in treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome.Type: ApplicationFiled: April 21, 2016Publication date: August 18, 2016Applicant: Teva Pharmaceutical Industries, Ltd.Inventors: Joel Kaye, Nora Tarcic